Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ANNX

DatePrice TargetRatingAnalyst
3/1/2024$11.00Neutral → Overweight
JP Morgan
12/21/2023$4.00 → $6.00Neutral → Buy
BofA Securities
10/30/2023$11.00Overweight
Wells Fargo
5/26/2023$8.00 → $3.00Buy → Neutral
BofA Securities
5/25/2023$19.00 → $9.00Overweight → Neutral
JP Morgan
9/16/2022$12.00Buy
Jefferies
9/9/2022$15.00Buy
BTIG Research
11/30/2021$40.00Buy
HC Wainwright & Co.
More analyst ratings

$ANNX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on February 10, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the new non-executive employees received options to purchase 542,000 shares of Annexon common stock. The options carry a ten-year term and a

    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

    BRISBANE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced presentations on ANX007 in geographic atrophy (GA) at the Macula Society 48th Annual Meeting being held February 12-15 in Charlotte Harbor, Florida. ANX007 is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally in the eye with an intravitreal formulation. ANX007 is the only investigational therapy in GA to show significant vision preservation on

    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year

    ANX005 First Potential Targeted Therapy for Guillain-Barré Syndrome Advancing Towards 1H 2025 BLA Submission ANX007 First Potential Neuroprotective Therapy for Geographic Atrophy Expected to Complete Enrollment of Phase 3 ARCHER II Trial in 2H 2025 ANX1502 First Oral C1s Inhibitor On Track for Clinical Proof of Concept Data in 1Q 2025 Cash Runway into 2H 2026 to Achieve Key Milestones BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced

    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ANNX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ANNX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ANNX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ANNX
SEC Filings

See more

$ANNX
Leadership Updates

Live Leadership Updates

See more
  • Annexon Expands Board of Directors with Appointment of Commercial Executive William "BJ" Jones

    BRISBANE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the appointment of  William "BJ" Jones to its board of directors. Mr. Jones brings 30 years of U.S. and global commercial and launch experience in the biotechnology industry. "We are thrilled to add BJ to our board of directors at this transformative time for Annexon," said Douglas Love, president and chief executive officer of Annexon. "His deep commercial expertise and proven experience

    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio

    BRISBANE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain, and eye, today announced the strengthening of its senior leadership team with the appointment of Shikhar Agarwal, M.B.A. as senior vice president, head of commercial, Sunil B. Mehta, Pharm.D as senior vice president of medical affairs and Myoung Kim, PHD, M.A., M.B.A. as vice president of health economics and outcomes research. "We are excited to welcome Shikhar, Sunil and Myoung to the Annexon family as we prepare for commercial development of our flagship programs in Guillain-Barré Syndrome (

    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Turnstone Biologics Appoints William Waddill to its Board of Directors

    SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,

    $ANNX
    $ARWR
    $PTGX
    $TSBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

$ANNX
Financials

Live finance-specific insights

See more
  • Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

    Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS) Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements Conference Call and Webcast Today at 8:30 a.m. ET BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the

    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

    Single Infusion of ANX005 30 mg/kg Met Primary Endpoint, Delivering a Highly Statistically Significant and Clinically Meaningful 2.4-fold Improvement in GBS-DS vs. Placebo at Week 8, p=0.0058 ANX005 Demonstrated Early and Sustained Improvements in Key Secondary Endpoints Including Muscle Strength, Nerve Damage and Ventilation ANX005 Displayed Rapid Target Engagement and was Generally Well-Tolerated Across Doses Real-World Evidence (RWE) Comparability Data Expected in First Half 2025 Conference call and webcast today at 8:30 a.m. ET BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage platform of novel ther

    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

    BRISBANE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it will host a conference call and webcast on Tuesday, June 4, 2024, at 8:30 a.m. ET to discuss GBS phase 3 data. Conference Call and Webcast InformationThe live webcast and replay may be accessed by visiting Annexon's website here. The dial-in number is 1-877-407-0784 (U.S./Canada) or 1-201-689-8560 (international). The conference ID for all callers is 13747058. The Call me™ link may be accessed here. Participants can use guest

    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ANNX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more